Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tomas Philipson

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Forum for Health Economics & Policy|August 18, 2019
A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer TherapiesWarren Stevens, Tomas Philipson, Yanyu Wu, et al.
Health Affairs (Project Hope)|January 9, 2008
Drug licenses: a new model for pharmaceutical pricingDana P Goldman, Anupam B Jena, Tomas Philipson, et al.
The American Journal of Managed Care|January 19, 2013
Dynamic cost-effectiveness of oncology drugsYang Lu, John R Penrod, Neeraj Sood, et al.
Health Affairs (Project Hope)|January 7, 2011
The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial dataDana P Goldman, Darius N Lakdawalla, Jesse D Malkin, et al.
Health Affairs (Project Hope)|April 12, 2012
An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancerTomas Philipson, Michael Eber, Darius N Lakdawalla, et al.
The American Journal of Managed Care|January 19, 2013
The option value of innovative treatments in the context of chronic myeloid leukemiaYuri Sanchez, John R Penrod, Xiaoli Lily Qiu, et al.
Health Affairs (Project Hope)|April 12, 2012
How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapiesDarius N Lakdawalla, John A Romley, Yuri Sanchez, et al.
Annals of the New York Academy of Sciences|August 16, 2014
Clinical and economic outcomes of nutrition interventions across the continuum of careMarian de van der Schueren, Marinos Elia, Leah Gramlich, et al.
Health Affairs (Project Hope)|October 11, 2012
The large social value resulting from use of statins warrants steps to improve adherence and broaden treatmentDavid C Grabowski, Darius N Lakdawalla, Dana P Goldman, et al.
Journal of the National Cancer Institute|September 27, 2015
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP), Christopher Sweeney, Mari Nakabayashi, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Forum for Health Economics & Policy|August 18, 2019
A Cost-Benefit Analysis of Using Evidence of Effectiveness in Terms of Progression Free Survival in Making Reimbursement Decisions on New Cancer TherapiesWarren Stevens, Tomas Philipson, Yanyu Wu, et al.
Health Affairs (Project Hope)|January 9, 2008
Drug licenses: a new model for pharmaceutical pricingDana P Goldman, Anupam B Jena, Tomas Philipson, et al.
The American Journal of Managed Care|January 19, 2013
Dynamic cost-effectiveness of oncology drugsYang Lu, John R Penrod, Neeraj Sood, et al.
Health Affairs (Project Hope)|January 7, 2011
The benefits from giving makers of conventional 'small molecule' drugs longer exclusivity over clinical trial dataDana P Goldman, Darius N Lakdawalla, Jesse D Malkin, et al.
Health Affairs (Project Hope)|April 12, 2012
An analysis of whether higher health care spending in the United States versus Europe is 'worth it' in the case of cancerTomas Philipson, Michael Eber, Darius N Lakdawalla, et al.
The American Journal of Managed Care|January 19, 2013
The option value of innovative treatments in the context of chronic myeloid leukemiaYuri Sanchez, John R Penrod, Xiaoli Lily Qiu, et al.
Health Affairs (Project Hope)|April 12, 2012
How cancer patients value hope and the implications for cost-effectiveness assessments of high-cost cancer therapiesDarius N Lakdawalla, John A Romley, Yuri Sanchez, et al.
Annals of the New York Academy of Sciences|August 16, 2014
Clinical and economic outcomes of nutrition interventions across the continuum of careMarian de van der Schueren, Marinos Elia, Leah Gramlich, et al.
Health Affairs (Project Hope)|October 11, 2012
The large social value resulting from use of statins warrants steps to improve adherence and broaden treatmentDavid C Grabowski, Darius N Lakdawalla, Dana P Goldman, et al.
Journal of the National Cancer Institute|September 27, 2015
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP), Christopher Sweeney, Mari Nakabayashi, et al.
Pageof 2